Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Lung societies unveil new international classification of lung adenocarcinoma

01.02.2011
First revision since 2004 takes a multidisciplinary approach, includes newest research

Three of the world's top lung associations have published a new international multidisciplinary classification of lung adenocarcinoma, the first revision to the classification in six years.

The new classification is published in the February edition of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC).

"With the many rapid advances in lung adenocarcinoma affecting clinical, radiologic, pathologic, molecular and surgical aspects of this cancer, it was necessary to develop a new classification using an international multidisciplinary consensus committee," said Dr. William Travis, attending thoracic pathologist at Memorial Sloan Kettering Cancer Center in New York City. "Since lung cancer is the most common cause of cancer mortality worldwide and adenocarcinoma is the most common histologic subtype in most countries, this classification addresses a major public health problem."

The IASLC was the primary sponsor of the project, which was performed with support and scientific oversight from the American Thoracic Society and the European Respiratory Society. An international core panel of experts representing the three organizations was formed to conduct the review; it included oncologists/pulmonologists, pathologists, radiologists, molecular biologists and thoracic surgeons.

Unlike previous classifications published by the World Health Organization (WHO) in 1967, 1981 and 1999, which were written primarily by pathologists for pathologists, the new classification takes into account advances across diverse specialties in the understanding of lung adenocarcinoma. Although the 2004 revision introduced relevant genetics and clinical information, the new classification is the first to be based on an integrated multidisciplinary platform.

"All previous WHO classifications have been developed by pathologists with little input from other specialties," Travis said.

One of the key new recommendations is that epidermal growth factor receptor (EGFR) mutation testing be performed for patients with advanced lung adenocarcinoma, due to the predictive benefit for response rate and progression-free survival for mutation-positive patients who are treated with tyrosine kinase inhibitors.

A completely new aspect of this classification, which was not addressed in previous WHO classifications, is a section that addresses diagnosis and classification of non-small cell carcinoma in small biopsies and cytology, Travis said. "This is important because 70% of lung cancers present in advanced stages," Travis said. "This section not only provides new criteria for diagnosis of adenocarcinoma versus squamous cell carcinoma that includes use of special stains in difficult cases, but it also stresses the importance of preserving tissue for molecular studies."

There are three major clinical reasons why it is important for pathologists to distinguish adenocarcinoma from squamous cell carcinoma, particularly in advanced lung cancer:

adenocarcinoma or unspecified NSCLC should be tested for EGFR mutations, which would indicate responsiveness to EGFR tyrosine kinase inhibitors;
patients with adenocarcinoma or unspecified NSCLC respond better to pemetrexed therapy than those with squamous cell carcinoma;

potential life-threatening hemorrhage may occur in patients with squamous cell carcinoma who receive bevacizumab.

The new classification recommends discontinuing use of the term bronchioloalveolar carcinoma (BAC) as tumors previously classified under this term fall into five different places in the new classification.

New concepts of "adenocarcinoma in situ" and "minimally invasive adenocarcinoma" were introduced to define patients who should have 100% or near 100% disease-free survival, respectively.

About the Journal of Thoracic Oncology:

The Journal of Thoracic Oncology (JTO) is the official monthly journal of the International Association for the Study of Lung Cancer (IASLC). It is a prized resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer. It emphasizes a multidisciplinary approach, including original research (clinical trials and translational or basic research), reviews and opinion pieces.

To find out more about the JTO please visit journals.lww.com. To learn more about the IASLC please visit iaslc.org.

Renée McGaw | EurekAlert!
Further information:
http://www.ucdenver.edu

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>